Microsoft partners with Seattle-based Adaptive Biotech to build an AI-driven universal blood test that can screen for dozens of diseases at once
A tech giant partners … Thanks: @toddbishop
Context & Ripple Effects
This 2018 partnership is the opening move in what became a near-decade-long Microsoft healthcare buildout. Weeks after the Adaptive Biotech deal was announced, Microsoft rolled out four new services for healthcare professionals, including Microsoft Genomics, and by 2019 had added a Clinical Trials Bot connecting patients and drugmakers.
The blood-test bet also foreshadowed the company's later clinical claims and products: an AI diagnostic tool Microsoft says beats doctors on accuracy (80% vs. 20%), the GigaTIME tumor-analysis model built with Providence and UW, and consumer-facing offerings like Copilot Health and a Mayo Clinic-trained assistant. The Adaptive Biotech deal is where Microsoft first bought its way into biological data.
First-order effects
- Adaptive Biotech gains Microsoft's cloud and machine-learning muscle for its sequencing work, while Microsoft acquires a foothold in diagnostic biology it could not have built internally.
Second-order effects
- Academic medical centers become the next supply chain for Microsoft's models — the Mayo Clinic data partnership shows hospital datasets following the biotech-partnership template.
Third-order effects
- If the pattern holds, Microsoft vertically integrates the healthcare AI stack — lab tests, diagnostics, records, and patient-facing advice — concentrating in one vendor what hospitals, labs, and clinicians currently source separately, with regulators as the pacing factor.
The trend: Microsoft is assembling a full-stack healthcare AI business, moving from research partnerships over biological data toward consumer-facing diagnostic and advisory products.